Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.

Evelo Biosciences, Inc., a biotechnology company based in Delaware, has filed a Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on January 26, 2024, to deregister all unsold shares of its common stock previously registered under a Registration Statement on Form S-3. This action follows the company's board of directors' decision on November 21, 2023, to dissolve the company in accordance with the Delaware General Corporation Law and seek stockholder approval for the dissolution. The board determined that the dissolution is in the best interests of the company and its stakeholders. The filing of the Post-Effective Amendment is a formal step to terminate the effectiveness of the Registration Statements and remove from registration any unsold securities, effectively ending the offerings of securities under these statements.